

Clinical Trial Protocol

Iranian Registry of Clinical Trials

09 Jun 2026

The Effect of Sustainable Diet Combined with Time-Restricted Eating and Probiotic Supplementation on Cardiovascular Function among Patients with Chronic Heart Failure with reduced Ejection Fraction (HFrEF): A Randomized Clinical Trial Study

Protocol summary

Study aim

Preparation of LP299v Probiotic Supplements
Investigating of a sustainable diet in combination with TRE and probiotic supplements on cardiovascular function among patients with HFrEF

Design

A controlled clinical trial, parallel-group, single-blind, randomized, phase 3, among 90 HFrEF patients

Settings and conduct

This study is conducted in two phases, the probiotic capsule preparation phase and the clinical phase. The place of the study will be the cohort center of MUMS. After confirming the diagnosis of HFrEF by cardiologists, participants will be referred to the specialist for more detailed explanations if they participate in the project. After controlling inclusion criteria, the participants are assigned to one of the 3 study groups using stratified blocked randomization method and researcher and participants will be blinded. Also, unique codes generating by online website will be assigned on the medicinal container. As each person enters to study regarding to randomized consequences, medicinal container is assigned to person and no one (researcher and participants) know which participants will be in which intervention group. Medicine containers will also be opaque with closed lids and capsules will be the same in appearance, color, taste and smell.

Participants/Inclusion and exclusion criteria

Inclusion criteria: Clinical diagnosis of HFrEF Men and women with age range of 30-75 years, Complete the informed consent form
Exclusion criteria: Using nutritional supplements, Not consuming more than 20% of the capsules, Unwillingness to continue cooperation in research

Intervention groups

Participants will be randomly divided into 3 groups:

Dietary Advices + Probiotic Placebo: A Sustainable Diet with Time Restricted Eating + Probiotic Placebo: B
Sustainable Diet with Time Restricted Eating + Probiotic Capsule: C

Main outcome variables

Echocardiography, biochemical and anthropometric indices

General information

Reason for update

We kindly request an update to the trial record due to modifications in the title and certain aspects of the methods used.

Acronym

IRCT registration information

IRCT registration number: **IRCT20231225060520N1**

Registration date: **2024-01-23, 1402/11/03**

Registration timing: **prospective**

Last update: **2025-10-16, 1404/07/24**

Update count: **2**

Registration date

2024-01-23, 1402/11/03

Registrant information

Name

Pegah Rahbarinejad

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 21 8827 1524

Email address

pegah.rahbarinejad@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2025-04-04, 1404/01/15

Expected recruitment end date

2026-02-04, 1404/11/15

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

The Effect of Sustainable Diet Combined with Time-Restricted Eating and Probiotic Supplementation on Cardiovascular Function among Patients with Chronic Heart Failure with reduced Ejection Fraction (HFrEF): A Randomized Clinical Trial Study

Public title

The Effect of Diet with probiotic on Cardiovascular Function

Purpose

Supportive

Inclusion/Exclusion criteria

Inclusion criteria:

Clinical diagnosis of heart failure with echocardiogram showing systolic dysfunction with ejection fraction \leq 40% based on New York Heart Association (NYHA) class II-III heart failure symptoms with ischemic or non-ischemic etiology Under standard treatment with drugs Men and women with age range of 30-75 years Willingness to participate in the study and complete the informed consent form

Exclusion criteria:

Use of nutritional supplements (oral or injectable, such as vitamins D, C, E, calcium, magnesium, potassium, multivitamin- mineral, omega 3) and herbal products with antioxidant and anti-inflammatory properties, probiotic or synbiotic supplements or products containing them during the study Not consuming more than 20% of the capsules Unwillingness to continue cooperation in research

Age

From **30 years** old to **75 years** old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser

Sample size

Target sample size: **75**

Randomization (investigator's opinion)

Randomized

Randomization description

In this study, we will use stratified blocked randomization for random allocation. Body mass index (BMI) is considered as a classifier variable. By using the site www.sealdenvelope.com and the classifier variable (BMI) and selecting blocks of 6 on the site, a random sequence will be generated. The mentioned sequences are placed in opaque, numbered and sealed envelopes or SNOSE by the research associate. Upon entering each patient, after obtaining informed consent and checking the inclusion and non-inclusion and exclusion criteria, the first envelope is opened and the patient is assigned to one of the 3 relevant groups. In the same way, the randomization process will continue until the last patient. In order to apply concealment allocation in the random allocation process, unique codes will be used on medicine containers. So that the desired code is also generated by the online website. As each person enters the study based on the generated sequence, the medicine container in which the desired code is recorded is assigned to the person and therefore, before choosing the person, no one is aware of the type of treatment he/she will receive. Medicine containers are also non-transparent closed lids and capsules will be the same in terms of quantity, color, taste and smell.

Blinding (investigator's opinion)

Single blinded

Blinding description

This study is not blinded in terms of diet but will be blinded in terms of supplements. The probiotic supplement and its placebo will be produced by PARSILACT Company. All probiotic and its placebo supplements will be provided by PARSILACT Company in prepacked pharmaceutical polyethylene bottle numbered for each patient according to the randomization sequence. The probiotic supplement and its placebo will be in the same form package. The researcher and patients will not be aware of the pharmaceutical polyethylene bottle's content until the end of the trial.

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Mashhad University of Medical Sciences

Street address

Department of Nutrition, Faculty of Medicine, Ferdowsi University Campus, Azadi Square, Razavi Khorasan

City

Mashhad

Province

Razavi Khorasan

Postal code

9177948564

Approval date

2024-01-03, 1402/10/13

Ethics committee reference number

IR.MUMS.REC.1402.259

Health conditions studied**1****Description of health condition studied**

Patients with Chronic Heart Failure with reduced Ejection Fraction (HFrEF)

ICD-10 code

I50.9

ICD-10 code description

Heart failure, unspecified

Primary outcomes**1****Description**

N Terminal pro Natriuretic Peptide type B (NT-proBNP)

Timepoint

In the beginning of the study (before the start of the intervention) and 60 days after the intervention

Method of measurement

Kit for measuring N-terminal pro-natriuretic peptide type B in venous blood sample

Secondary outcomes

empty

Intervention groups**1****Description**

First Intervention group: Dietary advices + Probiotic placebo (without Lactobacillus plantarum 299v, twice daily for 60 days)

Category

Placebo

2**Description**

Second Intervention group: Sustainable diet combined with time-restricted eating + Probiotic placebo (without Lactobacillus plantarum 299v, twice daily for 60 days)

Category

Treatment - Other

3**Description**

Third Intervention group: Sustainable diet combined with

time-restricted eating + Probiotic Capsule (Lactobacillus plantarum 299v with a dose of 14 billion CFU, twice daily for 60 days)

Category

Treatment - Other

Recruitment centers**1****Recruitment center****Name of recruitment center**

Mashhad University of Medical Sciences

Full name of responsible person

Pegah Rahbarinejad

Street address

Department of Nutrition, Faculty of Medicine, Ferdowsi University Campus, Azadi Square, Mashhad, Razavi Khorasan

City

Mashhad

Province

Razavi Khorasan

Postal code

9177948564

Phone

+98 51 3882 7034

Email

pegah.rahbarinejad@gmail.com

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Mashhad University of Medical Sciences

Full name of responsible person

Mohsen Tafaghodi Piadeh Gheibi

Street address

Research and Technology Vice Chancellor, Qurashi Building, next to Hoize Cinema, University St., Mashhad, Razavi Khorasan

City

Mashhad

Province

Razavi Khorasan

Postal code

9138813944

Phone

+98 51 3841 1538

Fax**Email**

Tafaghodim@mums.ac.ir

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Mashhad University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Mashhad University of Medical Sciences

Full name of responsible person

Pegah Rahbarinejad

Position

Ph.D. Student

Latest degree

Ph.D.

Other areas of specialty/work

Nutrition

Street address

Department of Nutrition, Faculty of Medicine,
Ferdowsi University Campus, Azadi Square, Mashhad,
Razavi Khorasan

City

Mashhad

Province

Razavi Khorasan

Postal code

9177948564

Phone

+98 21 8827 1524

Fax

Email

pegah.rahbarinejad@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Mashhad University of Medical Sciences

Full name of responsible person

Pegah Rahbarinejad

Position

Ph.D. Student

Latest degree

Ph.D.

Other areas of specialty/work

Nutrition

Street address

Department of Nutrition, Faculty of Medicine,
Ferdowsi University Campus, Azadi Square, Mashhad,
Razavi Khorasan

City

Mashhad

Province

Razavi Khorasan

Postal code

9177948564

Phone

+98 21 8827 1524

Fax

Email

pegah.rahbarinejad@gmail.com

Person responsible for updating data

Contact

Name of organization / entity

Mashhad University of Medical Sciences

Full name of responsible person

Pegah Rahbarinejad

Position

Ph.D. Student

Latest degree

Ph.D.

Other areas of specialty/work

Nutrition

Street address

Department of Nutrition, Faculty of Medicine,
Ferdowsi University Campus, Azadi Square, Mashhad,
Razavi Khorasan

City

Mashhad

Province

Razavi Khorasan

Postal code

9177948564

Phone

+98 21 8827 1524

Fax

Email

pegah.rahbarinejad@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available